Trial Profile

An Open-label, Phase 1 Study to Investigate the Safety and Pharmacokinetics of SGN-B6A in Chinese Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sigvotatug vedotin (Primary)
Indications Adenocarcinoma; Carcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Seagen

Most Recent Events

21 Feb 2025 Planned End Date changed from 30 Sep 2025 to 7 Oct 2025.
21 Feb 2025 Planned primary completion date changed from 30 Sep 2025 to 7 Oct 2025.
24 Sep 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com